Vor Biopharma
102 hedge funds and large institutions have $893M invested in Vor Biopharma in 2026 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 35 increasing their positions, 19 reducing their positions, and 17 closing their positions.
129% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 17
84% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 19
28% more funds holding
Funds holding: 80 → 102 (+22)
25% more capital invested
Capital invested by funds: $717M → $893M (+$176M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
99% less call options, than puts
Call options by funds: $11K | Put options by funds: $1.19M
299.01% less ownership
Funds ownership: 388.53% → 89.52% (-299%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$51.3M |
| 2 |
BlackRock
New York
|
+$40.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$22.7M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$12.8M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$45.4M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$16M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$5.69M |
| 4 |
PBM
Propel Bio Management
Los Angeles,
California
|
-$5.59M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.27M |
VOR Hedge Fund Activity: Q2 2026 in Review
102 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q2 2026, worth a combined $893M — up 25% from $717M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new VOR positions and 17 closed out — a net gain of 22 holders — while 35 added to existing stakes and 19 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $51.3M. The largest seller was RA Capital Management, cutting an estimated $45.4M.
- 102 institutional investors held Vor Biopharma (VOR) as of Q2 2026, up from 80 in Q1 2026.
- Funds reported $893M of Vor Biopharma stock for Q2 2026, up 25% quarter-over-quarter.
- 39 funds opened new Vor Biopharma positions in Q2 2026 and 17 closed out, a net change of +22 holders.
- The largest Vor Biopharma buyer in Q2 2026 was Fidelity Investments, an estimated $51.3M added.
- The largest Vor Biopharma seller in Q2 2026 was RA Capital Management, an estimated $45.4M sold.
Based on aggregated 13F filings for Q2 2026.